Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without ...

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking ...

Use of the 1.5T Elekta Unity MR-Linac was associated with reduced rates of erectile dysfunction at 6, 12, and 18 months in ...

Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib requires proactive strategies including supportive medications, dose ...

T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical ...

Oncology nurses can enhance endometrial cancer recovery by fostering strong social support networks and improving ...

Infusion bays designed with nurse input provide patients the choice between privacy and community while allowing support from loved ones.

The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult patients with KRAS-mutated recurrent, low-grade serous ovarian cancer (LGSOC) ...

First year of therapy is particularly crucial: Sets trajectory for future treatment outcomes Establishes patterns that predict long-term disease control Determines potential for deeper molecular ...

Panelists discuss how health care providers can promote medication adherence by moving beyond labeling patients as noncompliant, instead investigating root causes such as adverse effects, financial ...